Antheia, Inc.

A major step forward for synthetic biology and pharmaceutical supply chains: Antheia, Inc. has fulfilled its first commercial order of thebaine, marking a new era for biomanufacturing in essential medicines. The power of biosynthetic production in meeting regulatory standards and scaling for global demand is becoming clear with this milestone. Read more: https://shorturl.at/G95mJ As we face supply chain vulnerabilities, this kind of progress is exactly what's needed to create a more resilient future. Congratulations to Christina Smolke and the Antheia team for proving the potential of biomanufacturing. This delivery is just the beginning—looking forward to seeing what’s next! #SyntheticBiology #PharmaInnovation #SupplyChainResilience #Biomanufacturing #Biotech

Our partner Antheia, Inc., pharmaceutical ingredient manufacturer transforming essential medicine supply chains, has just announced that it has delivered its first commercial order of #thebaine to a leading pharmaceutical customer. Antheia has continued to produce thebaine at commercial scale with #Olon Andrea Conforto VP CDMO Biotech, comments “We are proud of the contribution we’ve given to this milestone. The partnership between Antheia and Olon is extremely important for the pharmaceutical environment and, overall, for patient’s access to treatments and for the global health. By using Antheia synthetic biology technology and Olon manufacturing asset and experience, we can produce sustainable and quality medicines, not being subject to a fragile and sometimes unpredictable supply chain of #API sourced from nature. As we are doing in the collaboration with Antheia, we can support pharma companies in developing, optimizing and manufacturing for our partners a wide range of molecules” Read the full story here https://lnkd.in/dw2WAP-6

We're proud to announce that our first commercial order of thebaine has been delivered to a leading pharmaceutical customer. This full-scale order of our first biosynthetic product, thebaine, will be used in the manufacturing of critical medicines and demonstrates technological, commercial, and regulatory readiness. Today’s announcement is a landmark moment in Antheia’s trajectory and represents a significant step forward in our mission to transform supply chains and end shortages of essential medicines. Learn more: https://bit.ly/3NKgACn #Antheia #PharmaSupplyChains #Biomanufacturing

Next week, Antheia CEO and co-founder, Christina Smolke will join the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium Industry Day as a featured speaker on several panels throughout the two-day event. We’re looking forward to connecting with the BioMaP community and discussing the ways this consortium will advance critical technologies to build resilient, agile, and domestic pharma supply chains. https://bit.ly/3YkSUJP

The Antheia team spent last week at the heart of pharma at CPHI Milan connecting with our partners, customers, and industry peers. It was an insightful event that shed light on the opportunity we have to build more resilient pharmaceutical supply chains that support the needs of a growing global population. Looking forward to next year already! #Antheia #CPHIGlobal #Biomanufacturing #Pharma

One last chance to hear from Antheia’s CEO and co-founder, Dr. Christina Smolke at CPHI Milan this week. Join the upcoming panel to hear from thought leaders on how we can build a more diverse and inclusive pharma industry. See you soon!

This morning, CEO and co-founder, Dr. Christina Smolke joins the CPHI Milan roundtable to share her perspective on the key trends shaping the industry in 2025. Looking forward to an insightful discussion among industry leaders.

Happening soon at the Next-Gen Bio Theatre at CPHI Milan: CEO and co-founder, Dr. Christina Smolke is speaking on a panel of leading experts on the latest trends in #biomanufacturing. See you there!

We’re gearing up for an exciting week at CPHI Global in Milan. If you’re attending, be sure to join CEO and co-founder, Dr. Christina Smolke as she presents this week on everything from global trends in biomanufacturing to 2025 outlooks for pharma to the importance of diversity and inclusion in the industry. Add these sessions to your calendar!

CPHI Global kicks off tomorrow in Milan and the Antheia team will be onsite discussing all things biomanufacturing and pharma supply chains. If you’re interested in meeting with our attending team, be sure to reach out via the CPHI app: Christina Smolke, Richard Sherwin, Guerin Kob, Yen-Hsiang W. #Antheia #Biomanufacturing #Pharma #SupplyChains